Perry M. Elliott

Feb 2, 2024 | onlinelibrary.wiley.com | Ahmad Masri |Roberto Barriales-Villa |Perry M. Elliott

Introduction Non-obstructive hypertrophic cardiomyopathy (nHCM) is a growing segment of the population with hypertrophic cardiomyopathy (HCM); however, no evidence-based medical therapies have been shown to improve symptoms, quality of life, or exercise capacity.1 Aficamten is a next-in-class cardiac myosin inhibitor that targets hypercontractility and impaired myocardial relaxation.2 Aficamten appears to be safe and effective in patients with obstructive HCM (oHCM) studied in the phase 2...

Sep 28, 2023 | onlinelibrary.wiley.com | Perry M. Elliott |Balarama Gundapaneni |Pablo García-Pavía

LETTER TO THE EDITOR Reply to ‘Effects of tafamidis on heart failure hospitalization: The tale of the dog that did not bark’ Perry Elliott,  Corresponding Author Perry Elliott University College London, London, UK Corresponding author.